Global Cord Blood

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants. Global Cord Blood was founded on January 17, 2008 and is headquartered in Hong Kong.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Global Cord Blood Corp. operates as a holding company, which engages in providing cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. It provides parents of newborn infants with umbilical cord blood storage services. The company was founded on January 17, 2008 and is headquartered in Hong Kong.

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange LLC (“NYSE” or “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the ordinary shares of Global Cord Blood Corporation (the “Company”) — ticker symbol CO — from the NYSE. Trading in the Company's ordinary shares will be suspended immediately. NYSE Regulation halted trading in the Company's ordinary shares on September 23, 2022 and has now determined to commence delisting proceeding.

NYSE to Commence Delisting Proceedings Against Global Cord Blood Corporation (CO)

GEORGE TOWN, Cayman Islands and HONG KONG , April 13, 2023 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), a provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services in China, announced that it received a notice (the "Notice") on April 3, 2023 from the New York Stock Exchange ("NYSE") with respect to its failure to timely file on Form 6-K its semi-annual financials for the six-month period ended September 30, 2022 (the "Interim Financials") as required by NYSE Listing Standard 203.03.

GLOBAL CORD BLOOD CORPORATION ANNOUNCES FAILURE TO FILE INTERIM FINANCIALS

HONG KONG--(BUSINESS WIRE)--Global Cord Blood Corporation (NYSE: CO) (“GCBC” or the “Company”), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that an order was made by the Grand Court of the Cayman Islands (“Grand Court”) on September 22, 2022 (the “Order”) appointing Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited and Chow Tsz Nga Georgia of Grant T

Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands

NEW YORK--(BUSINESS WIRE)--Blue Ocean Structure Investment Company Ltd., (“Blue Ocean”) a significant shareholder of Global Cord Blood Corporation (the “Company” or “Global Cord”) (NYSE: CO), today announced the Grand Court of the Cayman Islands (the “Court”) issued an order granting the appointment of joint provisional liquidators (“JPLs”) for Global Cord, pursuant to section 104(2) of the Companies Act (2022 Revision) (the "Companies Act"), upon the application filed by Blue Ocean dated 22 Au

The Grand Court of the Cayman Islands Granted Blue Ocean's Application to Appoint Joint Provisional Liquidators for Global Cord Blood Corporation

HONG KONG , Aug. 16, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The filed Form 20-F includes audited financial statements for the fiscal year ended March 31, 2022.

Global Cord Blood Corporation Files Annual Report on Form 20-F

HONG KONG , July 6, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that an injunction order (the "Order") previously obtained by the Company on June 15, 2022 from the Grand Court of the Cayman Islands (the "Court") against Blue Ocean Structure Investment Company Limited ("Blue Ocean") was officially issued by the Court on July 6, 2022. The Order provides, among other things, that: Until further order of the Court, any resolution or resolutions ("Resolutions") that might be passed or purported to be passed at any extraordinary general meeting of the Company to be held or purporting to be held on June 16, 2022 ("the Purported EGM") or other meeting held or purporting to be held pursuant to a Notice of Extraordinary General Meeting dated June 3, 2022 (on June 16, 2022 or any other date) shall not take effect and shall not be implemented, and Blue Ocean must not: rely or purport to rely upon any such Resolutions; and/or seek to convene or convene any extraordinary general meeting of the Company or other meeting.

Global Cord Blood Corporation Obtained Injunction Order Against Blue Ocean in respect of Purported EGM

Incyte

Added 16,423 New Subscribers in 4QFY22 4QFY22 Revenues Down 1.7% YoY to RMB297.2 Million ($46.9 Million) 4QFY22 Gross Profit Down 0.5% YoY to RMB255.2 Million ($40.3 Million) 4QFY22 Operating Income Down 4.1% YoY to RMB142.1 Million ($22.4 Million) 4QFY22 Non-GAAP Operating Income Down 4.1% YoY to RMB153.9 Million ($24.3 Million) HONG KONG , July 5, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the fourth quarter and full year of fiscal 2022, ended March 31, 2022. Fourth Quarter Fiscal 2022 Highlights New subscribers decreased by 15.2% year-over-year ("YoY") to 16,423 due to anti-pandemic measures, as well as fewer newborns in our operating regions, while accumulated subscriber base expanded to 970,375[1].

Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2022

HONG KONG , June 16, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, is pleased to announce that Cellenkos, Inc. ("CLNK") recently announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") application to initiate a Phase 1b, open-label study of CK0804 as an add on therapy to ruxolitinib in patients with myelofibrosis who experience a suboptimal response to ruxolitinib. Details related to this news can be found via the following Cellenkos news announcement: Cellenkos Receives FDA Clearance of Investigational New Drug (IND) Application for CK0804 as Add on Therapy to Ruxolitinib for the Treatment of Myelofibrosis (prnewswire.com) Ms.

Global Cord Blood Corporation Announced Cellenkos Receives FDA Clearance of IND Application for CK0804 as Add on Therapy to Ruxolitinib for the Treatment of Myelofibrosis

NEW YORK--(BUSINESS WIRE)--Blue Ocean Structure Investment Company Ltd., (“Blue Ocean”) and shareholders representing over 75% of the outstanding shares of Global Cord Blood Corporation (the “Company” or “Global Cord”) (NYSE: CO) today announced the successful approval of all resolutions at the Global Cord Extraordinary General Meeting of Shareholders (“EGM”) held today. 104,369,577 shares out of 121,551,075 total outstanding shares of Global Cord voted in the EGM, which represents 85.86 percen

Shareholders Led by Blue Ocean Announce Successful Results of Extraordinary General Meeting of Global Cord Blood Corporation

HONG KONG , June 16, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, noticed that on June 3, 2022 Blue Ocean Structure Investment Company Limited (the "Petitioner") issued a notice which purported to convene an extraordinary general meeting of the Company ("Purported EGM") which is due to be held on June 16, 2022. The Company's position is that this EGM has not been validly convened.

Global Cord Blood Corporation Announces Purported EGM Is Not Validly Convened

NEW YORK--(BUSINESS WIRE)--Blue Ocean Structure Investment Company Ltd.,(“Blue Ocean”) announced today that shareholders representing no less than 75% of the outstanding shares of Global Cord Blood Corporation (the “Company” or “Global Cord”) (NYSE: CO), have called an Extraordinary General Meeting of Shareholders (“EGM”) as allowed by the Company's Articles. The EGM will be held at DLA Piper LLP (US), 1251 Avenue of the Americas, New York, NY 10020-1104, United States of America, on 16 June, 2

Shareholders Led by Blue Ocean Call Extraordinary General Meeting of Global Cord Blood Corporation Shareholders to Terminate its Proposed Acquisition of Cellenkos, Inc. and Elect New Board

NEW YORK--(BUSINESS WIRE)--Blue Ocean Structure Investment Company Ltd. (“Blue Ocean”), a significant shareholder of Global Cord Blood Corporation (the “Company” or “Global Cord”) (NYSE: CO), today announced that the Eastern Caribbean Supreme Court in the High Court of Justice of the Virgin Islands (the “Court”) granted an injunction order (“the Order”) enjoining Golden Meditech Stem Cells (BVI) Company Limited (“Golden Meditech”) from taking any steps on a purported share charge from Blue Ocea

Blue Ocean Announces Virgin Islands Court Grants Injunction Order Prohibiting Golden Meditech from Taking Any Steps on a Purported Share Charge from Blue Ocean or Pursuing the Removal of Blue Ocean's Representative as a Director of Global Cord Blood

NEW YORK--(BUSINESS WIRE)--Blue Ocean Structure Investment Company Ltd. (“Blue Ocean”), a significant shareholder of Global Cord Blood Corporation (the “Company” or “Global Cord”) (NYSE: CO), today commented on what Blue Ocean believes to be a shocking, distracting and fraudulent Schedule 13D filing made by Golden Meditech Stem Cells (BVI) Company Limited (“Golden Meditech”) with the U.S. Securities and Exchange Commission. Blue Ocean, whose investment in Global Cord represents an ownership pos

Blue Ocean Comments on Fraudulent Claims from Conflicted Party Golden Meditech Regarding Global Cord Blood Corporation

HONG KONG , May 10, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, announced today that the Company has received a copy of a petition that was filed with the Grand Court of the Cayman Islands by Blue Ocean Structure Investment Company Limited ("Blue Ocean"). The Company is taking legal advice in response to Blue Ocean's petition and will make further announcements as appropriate in due course.

Global Cord Blood Corporation Announces Receipt of Blue Ocean Petition

Global Cord has delivered better results than expected over the last three quarters with 10% y/y rev growth and 18% profit growth. Sanpower completing its restructuring may facilitate capital return or Global Cord being acquired by Sanpower.

Pounce On Global Cord For The Year Of The Tiger

Banco BBVA Argentina SA

Good Times Restaurants

3 penny stocks to consider buying as they are undervalued, have low levels of debt and strong anticipated EPS growth. The post 3 Hot Penny Stocks to Buy in Q1 for Huge Potential appeared first on InvestorPlace.

3 Hot Penny Stocks to Buy in Q1 for Huge Potential

Global Cord Blood Corporation (CO) on Q3 2022 Results - Earnings Call Transcript

Added 18,985 New Subscribers in 3Q22 Revenues Up 9.1% YoY to RMB317.2 Million ($49.8 Million)         Gross Profit Up 9.8% YoY to RMB269.9 Million ($42.4 Million) Operating Income Up 20.8% YoY to RMB149.7 Million ($23.5 Million) Non-GAAP Operating Income Up 18.6% YoY to RMB161.6 Million ($25.4 Million) Conference Call to be Held on March 1, 2022, at 8:00 a.m. ET HONG KONG, Feb. 28, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the third quarter and first nine months of fiscal 2022, ended December 31, 2021.

Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2022

HONG KONG, Feb. 23, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release its financial results for the third quarter and first nine months of fiscal 2022 on Monday, February 28, 2022, after the U.S. market close.  The Company will host a conference call at 8:00 a.m.

Global Cord Blood Corporation to Report Third Quarter and First Nine Months Fiscal 2022 Financial Results

HONG KONG, Dec. 16, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that its Board of Directors (the "Board") decided to reject the non-binding proposal letter ("Alternate Ocean Proposal") from Alternate Ocean Investment Company Limited ("Alternate Ocean") received by the Board dated March 2, 2021, pursuant to which Alternate Ocean proposed to acquire all outstanding ordinary shares of the Company for US$5.00 per ordinary share in cash, based on the recommendation from a special committee of independent directors (the "Special Committee").  The Special Committee and the Board believe such proposal in its original form fails to properly reflect the value of the Company and maximize shareholder value.

Global Cord Blood Corporation Announces Rejection of Alternate Ocean Proposal

HONG KONG, Dec. 7, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2021 Annual General Meeting of shareholders, held on December 7, 2021, in Hong Kong S.A.R., China. At the Annual General Meeting, the Company's shareholders ratified the re-appointment of KPMG Huazhen LLP as independent auditors of the Company for the financial year ending March 31, 2022, and authorized any duly formed committee of the directors to fix the remuneration of the independent auditors; and re-elected Ms.

Global Cord Blood Corporation Announces Results of 2021 Annual General Meeting

Revenues increased 10% this quarter. The company grew in subscribers count this quarter and this was a positive sign.

Global Cord Blood: With 6.0x P/E And 24% EPS CAGR, Subscriber Growth Continues

Global Cord Blood Corporation (CO) Q2 2022 Results - Earnings Call Transcript

Added 19,066 New Subscribers in 2Q22 Revenues Up 9.8% YoY to RMB313.7 Million ($48.7 Million)         Gross Profit Up 11.0% YoY to RMB267.5 Million ($41.5 Million) Operating Income Up 15.3% YoY to RMB160.5 Million ($24.9 Million) Non-GAAP Operating Income Up 14.1% YoY to RMB172.8 Million ($26.8 Million) Conference Call to be Held on November 26, 2021, at 8:00 a.m. ET HONG KONG, Nov. 24, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the second quarter and first half of fiscal 2022 ended September 30, 2021.

Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2022

HONG KONG, Nov. 17, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release financial results for the second quarter and first half of fiscal 2022 on Wednesday, November 24, 2021, after the U.S. market close.  The Company will host a conference call at 8:00 a.m.

News for Global Cord Blood Stock (CO)